Adrenomyeloneuropathy (AMN) is a rare hereditary disease that affects approximately 30,000 people worldwide. Even though most people have never heard of AMN, it continues to be a very important focus for Nutra Pharma’s drug development.
Our goal is to receive the approval to launch the first-ever treatment for AMN using our lead drug candidate for autoimmune […]

Read Full Post »

Congratulations to David Isserman for launching RareShare, a social enterprise website for patients and families affected by rare medical disorders. The Site hosts over 600 communities, each dedicated to specific rare condition.
Although the Site is not owned by or affiliated with Nutra Pharma, David came up with the idea to launch the Site through his communications […]

Read Full Post »